Type | Researcher(s) involved | Event (Title, location, dates) | Activity title (e.g. title of poster or talk, etc.) |
Type of audience | Estimated persons reached |
---|---|---|---|---|---|
Participation to a conference | P1 - CHARITE: L. Amini, Schmueck-Henneresse | 1ST IMMUNOLOGY & INFLAMMATION CONFERENCE, 24. - 26.02. 2019 | Immunosuppressant-resistant T cells for advanced adoptive T cell therapy in immunosuppressed patients | Scientific Community (Higher Education, Research) | >1000 |
Participation to an event other than a conference or workshop | P1 - CHARITE: P. Reinke | British German Alliance for Advanced Therapies, British Embassy, Berlin (Germany), 26.03.2019 | ReSHAPE by next generation Treg approaches - An EU Consortium coordinated by BeCAT | Policy Makers | 53 |
Participation in activities organised jointly with other H2020 project(s) | P1 - CHARITE: H.-D. Volk; P. Reinke | Kick-off meeting of the RESTORE community, Berlin (Germany), 06.-07.05.2019 | Promoting Advanced therapies and strenghten the development of Advanced Therapies in the European market | Other | >320 |
Participation to a conference | P1 - CHARITE: L. Amini, Schmueck-Henneresse | Allogenic Cell Therapies Summit, 7.-9.05.2019 | Antiviral and CAR-T cell products for advanced adoptive T cell therapy | Scientific Community (Higher Education, Research) | >100 |
Participation to a conference | P1 - CHARITE: P. Reinke; J. Wendering; L.Amini | FOCIS Annual Meeting 2019, Boston (US), 18.-21.06.2019 | Next-Generation Regulatory T Cell Therapy; The Value of a Rapid Test of Huamn Regulatory T Cell Function Needs to be Revised (poster) | Scientific Community (Higher Education, Research) | >1060 |
Participation to a conference | P1 - CHARITE: L. Amini | Cell & Gene Therapy Bioprocessing & Commercialization, 9.-12.09.2019 | Investors | >2000 | |
Participation to a conference | P1 - CHARITE: P. Reinke | Phacilitate Leader Europe 2019, London (UK), 17.-18.09.2019 | RESTORE/RESHAPE faces challenges in manufacturing of Advanced Therapies | Scientific Community (Higher Education, Research) | >350 |
Participation to a conference | P1 - CHARITE: P. Reinke; L.Amini | 7th Annual Conference of the German Stem Cell Network, Berlin (Germany), 23.-25.09.2019 | Next-generation regulatory T cell products - opportunities and challenges | Scientific Community (Higher Education, Research) | >400 |
Participation to an event other than a conference or workshop | P1 - CHARITE: P. Reinke | Promoting Translational Research in University Medicine, Berlin (Germang), 08.12.2019 | Early clinical trials with ATMPs | Scientific Community (Higher Education, Research) | >100 |
Participation to an event other than a conference or workshop | P1 - CHARITE: P. Reinke; N. M. Otto, Schmueck-Henneresse | RegMed Forum 2019: cell and gene therapies, Berlin (Germany), 22.10.2019 | Regulatory T cells: A treatment option for balancing immune responses; Regulatory T cell therapy in solid organ transplantation; | Other | >120 |
Participation in activities organised jointly with other H2020 project(s) | P1 - CHARITE: H.-D. Volk; P. Reinke; L. Amini, Schmueck-Henneresse | RESTORE: 1st Advanced Therapy Science Meeting, Berlin (Germany), 25.-26.11.2019 | RESTORE - Health by Advanced Therapies - Opportunities and Challenges; Reshape immune balance by next-generation regulatory T cells; | Other | 400 |
Participation to a conference | P1 - CHARITE: Julia Polansky-Biskup | RESTORE: 1st Advanced Therapy Science Meeting, Berlin (Germany), 25.-26.11.2019 | invited talk: Epigenetic control of T cell differentiation: From genome-wide signatures to local regulators and their targeted manipulation. | Scientific Community (Higher Education, Research) | 400 |
Participation to a conference | P1 - CHARITE: L. Amini, Schmueck-Henneresse | The Hitchhiker’s Guide to Regenerative Therapies, 03.-06.12.2019 | Immunosuppressant-resistant antiviral and regulatory T cell products for advanced adoptive T cell therapy in immunosuppressed patients | Scientific Community (Higher Education, Research) | >100 |
Brokerage event | P1 - CHARITE: P. Reinke, H.-D. Volk | Cooperation Meeting Lonza Therapeutics, 16.09.2020 | T cell therapy/products | Industry | 4 |
Participation to a conference | P1 - CHARITE: P. Reinke | 29th Annual Meeting, German Transplantation Society (Deutsche Transplantationsgesellschaft / DTG), 17.10.2020 | Presentation: T cell monitoring | Scientific Community (Higher Education, Research) | ca. 500 |
Brokerage event | P1 - CHARITE: P. Reinke, H.-D. Volk | Follow-up - Cooperation Meeting Charité - Lonza Therapeutics, 28.10.2020 | T cell therapy/products | Industry | 7 |
Participation to a conference | P1 - CHARITE: P. Reinke | 20th Annual Meeting of the Federation of Clinical Immunology Societies, FOCIS, 30.10.2020 | Presentation: ReSHAPE Undesired Immunoreaction in Transplantation | Scientific Community (Higher Education, Research) | >1000 |
Organisation of a Conference | P1 - CHARITE: J. Polansky | Symposium on "Epigenetic in Development and Regeneration", CRTD Dresden, 24.11.2020 | From genome-wide signatures to local regulators and their targeted manipulation | Scientific Community (Higher Education, Research) | 80 |
Participation to an event other than a conference or workshop | P1 - CHARITE: P. Reinke, M. Schmück-Henneresse, L. Amini, D. Wagner, A. Römhild, D. Kaiser, M. Abou El Enein, R. Öllinger, H.-D. Volk | PEI (Paul Ehrlich Institut)- Scientif Advice Meeting, 12.11.2020 | Next-Generation regulatory T cell (Treg) Product, TaRTreg01,using CRISPR-Cas9-mediated gene-editing technology | Authory / Federal Institution | 19 |
Participation on event other than a conference or workshop | P1 - CHARITE: P. Reinke | RegMed Forum 2020 - Viruses and heart diseases, 01.12.2020 | Presentation: "Regulatory T-cells: a potential Treatment for inflammatory cardiomyopathy/myocarditis" | other | 100 |
Brokerage event | P1 - CHARITE: P. Reinke | Follow-up Meeting: Universitätsklinikum Leipzig, Leipzig (Germany), 03.12.2020 | Next steps: ProTreg Study Importance of regulatory and antigen-specific T cells in kidney transplantation | Scientific Community (Higher Education, Research) | 5 |
Participation to a conference | P1 - CHARITE: D.L. Wagner | Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome | EK24 09.03.2021 | Oral presentation, title: Fast and Efficient Generation of TRAC-integrated CAR T Cells without Viruses, | Scientific Community (Higher Education, Research) | >500 |
Brokerage event | P1 - CHARITE: P. Reinke, D. Kaiser, A. Römhild, L. Amini, D. Wagner, M. Schmück-Henneresse, H.-D. Volk, E. Fritsche, J. Kaeda, H. Schmidts, J. Polansky | Cooperation Meeting AstraZeneca, 18.03.2021 | Treg cell therapy | Industry | 20 |
Participation to an event other than a conference or workshop | P1 - CHARITE: P. Reinke | KHP and EUHA "Meet the expert" global clinical seminar series, 30.03.2021 | Presentation: Are regulatory T cells a realistic therapeutic option in solid organ transplantation? | Scientific Community (Higher Education, Research) | 55 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild, D. Kaiser | Cooperation Meeting CellCopedia, 13.04.2021 | Development and marketing of medical technology for the selection of cells | Industry | 8 |
Brokerage event | P1 - CHARITE: P. Reinke | Ruhr-Universität Bochum, Bochum (Germany), | kick off Meeting clin. Study | Scientific Community (Higher Education, Research) | 5 |
Brokerage event | P1 - CHARITE: P. Reinke, H.-D. Volk | Follow up Cooperation Meeting AstraZeneca, 12.05.2021 | Treg strategy | Industry | 4 |
Brokerage event | P1 - CHARITE: P. Reinke | Cooperation Meeting Sarstedt, 20.05.2021 | Discussion on the development of a monovette with AMG-compliant Na citrate for blood sampling for the production of cell products | Industry | 11 |
Brokerage event | P1 - CHARITE: P. Reinke, L. Amini, H.-D. Volk, D. Wagner, D. Kaiser | Follow up - Cooperation Meeting AstraZeneca, 26.05.2021 | Treg strategy | Industry | 15 |
Brokerage event | P1 - CHARITE: P. Reinke | Follow up - Coorperation Meeting CellCopedia, CellDot, 07.06.2021 | Development and marketing of medical technology for the selection of cells | Industry | 3 |
Participation to a conference | P1 - CHARITE: J. Polansky | Annual meeting german society for Immunology, clinical immunology, 23.06.2021 | Utilizing epigenetics for the benefit of advanced therapies | Scientific Community (Higher Education, Research) | 60 |
Brokerage event | P1 - CHARITE: P. Reinke, H.-D. Volk | Follow up Coorperation Meeting CellCopedia, 28.06.2021 | Development and marketing of medical technology for the selection of cells / discussion exploitation | Industry | 8 |
Brokerage event | P1 - CHARITE: P. Reinke | Cooperation Meeting Fraunhofer IBMT, 30.07.2021 | cryoconservation regT Cells | other | 5 |
Brokerage event | P1 - CHARITE: P. Reinke | Coorperation Meeting Fraunhofer IBMT - UZ Leuven - Charité, 05.08.2021 | project discussion T Cells | other | 14 |
Brokerage event | P1 - CHARITE: P. Reinke, H.-D. Volk, A. Römhild, L. Amini, M. Schmück-Henneresse | Follow up - Cooperation Meeting AstraZeneca, 09.09.2021 | further discussion Treg strategy | Industry | 10 |
Brokerage event | P1 - CHARITE: P. Reinke | Follow up - Cooperation Meeting Fraunhofer IBMT, 14.09.2021 | further steps, cryoconservation reg Te Cells | other | 2 |
Brokerage event | P1 - CHARITE: P. Reinke | Follow up Coorperation Meeting CellCopedia, 27.09.2021 | Development and marketing of medical technology for the selection of cells / discussion exploitation | Industry | 2 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild, D. Kaiser | Follow up - Cooperation Meeting Fraunhofer IBMT, 28.09.2021 | further steps, cryoconservation reg Te Cells | other | 6 |
Brokerage event | P1 - CHARITE: P. Reinke, H.-D. Volk | Cooperation Meeting Florabio, 11.10.2021 | cell media development | Industry | 3 |
Participation to a conference | P1 - CHARITE: P. Reinke | Nederlandse Nefrologiedagen, 13.10.2021 | Presentation: Are regulatory T cells a realistic option in solid organ transplantation ? | Scientific Community (Higher Education, Research) | >300 |
Brokerage event | P1 - CHARITE: P. Reinke, D. Wagner | Follow up - Cooperation Meeting LONZA, 14.10.2021 | new technologies in manufactoring Treg Cells | Industry | 5 |
Participation to an event other than a conference or workshop | P1 - CHARITE: D.L. Wagner | Virtual World CRISPR Day 20.10.2021 | Oral presentation, title: Engineering designer T cell immunotherapies for transplant medicine and oncology | General Public | >12000 |
Participation to a conference | P1 - CHARITE: J. Kath | Annual congress of the European Society for Gene and Cell Therapy 19-21.10.2021 | Oral presentation, title: OR06: Improved non-viral CAR-reprogramming of human T cells using CRISPR-Cas and double-stranded DNA | Scientific Community (Higher Education, Research) + Industry | >600 |
Participation to an event other than a conference or workshop | P1 - CHARITE: M. Schmueck-Henneresse | Berlin Science Week: CELLS - MEDICINE OF THE FUTURE?, 12.11.2021 | Oral presentation: With immune cells against diseases | General Public | >100 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild | Follow up - Cooperation Meeting Fraunhofer IBMT, 15.11.2021 | further steps, cryoconservation reg Te Cells | other | 5 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild, L. Amini, D. Wagner | Follow up - Cooperation Meeting AstraZeneca, 17.11.2021 | discussion on structuring collaboration | Industry | 10 |
Participation to a conference | P1 - CHARITE: P. Reinke | Workshop Focis Goes South 2021, 17.11.2021 | "Presentation: Are regulatory T cells a realistic therapeutic option in solid organ transplantation?" | Scientific Community (Higher Education, Research) | >500 |
Organisation of a Conference | P1 - CHARITE: D.L. Wagner | RegMed Forum 2021, The multifaceted potential of CRISPR-Cas9 in medicine, Berlin (Germany) 25.11.2021 | CRISPR-Cas9 for basic research and cell therapy applications | Scientific Community (Higher Education, Research) + Industry | >100 |
Participation to a conference | P1 - CHARITE: L. Amini, Schmueck-Henneresse, D.L. Wagner | RegMed Forum 2021, The multifaceted potential of CRISPR-Cas9 in medicine, Berlin (Germany) 25.11.2021 | Oral presentations: TacRes Tregs, The Evolution of CRISPR-Cas9 technology | Scientific Community (Higher Education, Research) + Industry | >100 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild, D. Kaiser | Follow up - Cooperation Meeting Fraunhofer IBMT, 29.11.2021 | further steps, cryoconservation reg Te Cells | other | 6 |
Participation to a conference | P1 - CHARITE: L. Amini, M. Schmück-Henneresse, G. Zarrinrad | Adeep dive into science, Berlin, 29.11.-02.12.2021 | Oral presentation: A new generation of tacrolimus-resistant regulatory T cell products for advanced adoptive T cell therapy in solid organ transplantation | Scientific Community (Higher Education, Research) | >100 |
Brokerage event | P1 - CHARITE: P. Reinke | Follow up - Cooperation Meeting Charité - Lonza Therapeutics, 01.12.2021 | new technologies in manufactoring Treg Cells | Industry | 2 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild, L. Amini, D. Wagner | Follow up - Cooperation Meeting AstraZeneca, 14.12.2021 | further steps discussion on structuring collaboration | Industry | 2 |
Participation to a conference | P1 - CHARITE: B. Sawitzki | BIH Welcome Symposium, Berlin - online meeting, 15.12.2021 | Strategies to increase Treg stability | Scientific Community (Higher Education, Research) | 100 |
Brokerage event | P1 - CHARITE: P. Reinke, A. Römhild, L. Amini, D. Wagner | Follow up - Cooperation Meeting AstraZeneca, 20.12.2021 | Treg manufactoring | Industry | 2 |
Participation to a conference | P1 - CHARITE: Leila Amini | NAT & IGO virtual meeting: "New horizons in immunotherapy", online, May 31st and June 1st, 2021 | Oral presentation: Immunosuppressant-resistant T cell products for improved functionality in immunosuppressed patients | Scientific Community (Higher Education, Research) | 230 |
Participation to a conference | P1 - CHARITE: Leila Amini | RegMed Forum, Berlin, November 25th, 2021 | oral presentation: CRISPR-based immune cell therapies: Immunosuppressant-resistant T cells for improved adoptive T cell therapy | Scientific Community (Higher Education, Research) + Industry | 50 |
Brokerage event | P1 - CHARITE: D.L.Wagner | Collaboration Meeting: Integrated DNA Technologies - Datum fehlt noch | Improving HDR in T cells | ||
Participation to a conference | P4 - UOXF: Fadi Issa | "Nanostring EU Summits: Crosstalk" 23 Oct 2019, Birmingham, UK | "How nanoString can enrich transplant studies" - talk | Scientific Community (Higher Education, Research) | 100 |
Participation to a conference | P4 - UOXF: Fadi Issa | International Transplantation Science Meeting, 10 - 13th November 2019, Clearwater Beach, Florida, USA | Scientific Community (Higher Education, Research) | 200 | |
Participation to an event other than a conference or workshop | P4 - UOXF: Joanna Hester | RESTORE: 1st Advanced Therapy Science Meeting, Berlin (Germany), 25.-26.11.2019 | "The TWO Study – A Phase II Trial of Regulatory T Cell Therapy in Renal Transplantation" - poster | Scientific Community (Higher Education, Research) | 400 |
Participation to a conference | P4 - UOXF: Fadi Issa | The 4th International Workshop on Clinical Tolerance | Update on the Oxford/London ONE and TWO Studies | Scientific Community (Higher Education, Research) | 100 |
Participation to an event other than a conference or workshop | P5 - Markus Templin | Virologisch-wissenschaftliches Kolloquium University Clinic Tübingen Germany | Talk: Multiplexed Immunoassays - Characterisation of Immune Cells | Scientific Community (Higher Education, Research) | 60 |
Participation to a conference | P5 - NMI: Markus Templin | Analytica 2020 München (Germany) 19.-23.10.2020 | "Profiling of cellular signalling pathways using a multiplexed Western Blot" - talk | Scientific Community (Higher Education, Research) | 400 |
Participation to an event other than a conference or workshop | P6 - CTC: Ilaria Santeramo | CGTC's regular lab meeting, CGTC, 21 August 2019 | Internal talk | Scientific Community (Higher Education, Research) | 50 |
Participation to a conference | P7 - TissUse | WC11 Virtual Congress, 23-27.08.2021 | Oral presentation, title: Establishment of a multi-organ-chip platform to replace animal transplant models for preclinical evaluation of Treg cell therapies | Scientific Community (Higher Education, Research) | 100 |
Web-site | P9 - INNACTA | RESHAPE Website Regular Updates | Other | 1.000 | |
Participation to a conference | P10 - Ignacio Anegon | FOCISed in South East Asia 1st Annual Course: Advances in Immunology, Immune Monitoring, and Immunotherapy. Jaipur, India. March 26-29, 2019. | talk | Scientific Community (Higher Education, Research) | 120 |
Participation to a conference | P10 - UN Ignacio Anegon | Latin American Society for Immunology and French Society for Immunology joint meeting. FOCIS annual meeting. Cancun, Mexico. June 18th 2019. I. Anegon. CD8+ Tregs in transplantation. | talk | Scientific Community (Higher Education, Research) | 100 |
Participation to a conference | P10 - UN Carole Guillonneau | 3) Day of Immunotechnologies, Institut Gustave Roussy, Paris, France. 26th Septembre 2019. C. Guillonneau, Anti-CD45RC to eliminate Teffs and induce Tregs in transplantation and autoimmune diseases | talk | Scientific Community (Higher Education, Research) | 150 |
Participation to a conference | P10 - UN Carole Guillonneau | ThymE: T cell and thymus biology, Rehovot, Israel 19-23 May 2019. C. Guillonneau, Anti-CD45RC to eliminate Teffs and induce Tregs in APECED disease. | talk | ||
Participation to a conference | P10 - UN | What’s up in Immunotherapy, 31st January 2019, C. Guillonneau, Nantes, France. Anti-CD45RC to eliminate Teffs and induce Tregs in transplantation and autoimmune diseases. | talk | ||
Participation to a conference | P10 - UN Séverine Bézie | ThymE: T cell and thymus biology. Rehovot, Israel, 19-23 May 2019. S. Bézie (poster) Human CD8+ Treg mediated inhibition of GVHD and human skin rejection in NSG mice. | |||
Participation to a conference | P10 - UN Carole Guillonneau | Annual Meeting of the French Society for Immunology, Nantes, France. 12-14rd November 2019 | oral presentation, title: Anti-CD45RC to eliminate Teffs and induce Tregs in transplantation and autoimmune diseases. | ||
Participation to a conference | P10 - UN Séverine Bézie | Annual Meeting of the French Society for Immunology, Nantes, France. 12-14th November 2019 | Oral presentation, title: Human CD8+ Treg suppress human skin rejection and GVHD in NSG mice. | ||
Organisation of a Conference | P10 - UN Ignacio Anegon | 22e NAT-IGO Congress: "New horizons in immunotherapy" (31/05-01/06-2021) | Scientific Committe | Scientific Community (Higher Education, Research) | 250 |
Participation to a conference | P10 - UN Ignacio Anegon | 5th French international symposium on CAR T-cell therapy (CAR T Day 2021) that took place in Lille, France, on September 2-4, 2021. | Invited talk. CAR Treg in organ transplantation, GVHD and autoimmunity. | Scientific Community (Higher Education, Research) | 300 |
Participation to a conference | P10 - UN Ignacio Anegon | 3rd Transplantchild Workshop. Madrid. November 11th, 2021. | Invited talk. A new mAb tolerogenic therapy in organ transplantation, GVHD and genetic autoimmune diseases. | Scientific Community (Higher Education, Research) | 100 |
Organisation of a workshop | P10 - UN Ignacio Anegon | 2nd FOCIS Goes South Meeting. Santiago de Chile (virtual). November 11th, 2021 | Invited talk. Anti-CD45RC mAb therapy tolerogenic therapy. | Scientific Community (Higher Education, Research) | 750 |
Organisation of a workshop | P10 - UN Ignacio Anegon | Inaugural FOCIS Advanced Course in Translational and Clinical Immunology. China (on line). December 4h, 2021. | Ornad and bone marrow transplantation. | Scientific Community (Higher Education, Research) | 1.800 |
Participation to a conference | P10 - UN Carole Guillonneau | FOCIS 2020, 28-31.10.2020 | e-oral "Anti-CD45RC to eliminate Teffs and induce Tregs in transplantation and autoimmune diseases." | Scientific Community (Higher Education, Research) | 100 |
Participation to a workshop | P10 - UN Carole Guillonneau | TLJ2.0 organized by the European Society for Organ Transplantation (ESOT) | e-oral presentation, title: "Cell therapy using CD8+Tregs in human transplantation" | Scientific Community (Higher Education, Research) | 100 |
Participation to a conference | P10 - UN Carole Guillonneau | TTS 2020 Virtual Congress, 14-16.09.2020 | e-oral "Anti-CD45RC to eliminate Teffs and induce Tregs in transplantation and autoimmune diseases." | Scientific Community (Higher Education, Research) | 3.500 |
Organisation of a Conference | P10 - UN Carole Guillonneau | 22e NAT-IGO Congress: "New horizons in immunotherapy" (31/05-01/06-2021) | Chairwoman | Scientific Community (Higher Education, Research) | 250 |
Participation to a conference | P10 - UN Séverine Bézie | Annual Meeting of the French Society for Immunology, Nantes (France), 12-14.11.2019 | Oral presentation, title: Human CD8+ Treg suppress human skin rejection and GVHD in NSG mice. | Scientific Community (Higher Education, Research) | 500 |
Participation to a conference | P10 - UN Séverine Bézie | TTS 2020 Virtual Congress, 14-16.09.2020 | e-Poster presentation, title: "Cell therapy using CD8+Tregs in human transplantation" | Scientific Community (Higher Education, Research) | 3.500 |
Participation to a conference | P10 - UN Séverine Bézie | FOCIS 2020, 28-31.10.2020 | e-oral and e-poster presentation, title: "Cell therapy using CD8+Tregs in human transplantation" | Scientific Community (Higher Education, Research) | 100 |
Press releases and other dissemination material will be available soon.